Investors

Overview

Tourmaline is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases.

Change
Volume
January 6, 2025 3:48 AM EST

Minimum 15 minutes delayed. Source: LSEG

background image

News

December 10, 2024
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
Read More
November 14, 2024
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
Read More
November 7, 2024
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Read More

Events

December 10, 2024 10:00 AM EST
Investor Day
Read More
November 12, 2024 1:30 PM EST
Guggenheim Securities Healthcare Innovation Conference
Read More
November 1, 2024 9:30 AM EDT
Expert Webinar with Dr. Dipender Gill: Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease
Read More

Presentation

December 10, 2024
Tourmaline Corporate Overview - December 2024
Read More

Investor Information

Investor Contact

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com